
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Gross Profit 2011-2026 | EPZM
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 10.7 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.7 M | 10.7 M | 10.7 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
-104 K | $ 0.82 | 3.61 % | $ 4.47 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | ||
|
Athersys
ATHX
|
1.44 M | - | 3.77 % | $ 22.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
4.77 M | - | - | $ 521 M | ||
|
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | ||
|
BridgeBio Pharma
BBIO
|
38.1 M | $ 65.12 | 0.91 % | $ 12.5 B | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 59.06 | 0.91 % | $ 11.3 B | ||
|
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
4.15 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
CTI BioPharma Corp.
CTIC
|
4.2 K | - | - | $ 1.2 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
5.88 K | - | -5.98 % | $ 34.1 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.94 M | - | -4.36 % | $ 27 M | ||
|
Cabaletta Bio
CABA
|
0.006 | $ 3.25 | 0.03 % | $ 3.8 M | ||
|
Capricor Therapeutics
CAPR
|
310 | $ 25.35 | -1.92 % | $ 679 M | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
Codexis
CDXS
|
52.8 M | $ 0.97 | -1.14 % | $ 71.2 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Certara
CERT
|
129 M | $ 7.44 | 2.69 % | $ 1.19 B | ||
|
Coherus BioSciences
CHRS
|
339 M | $ 1.71 | 3.33 % | $ 161 M | ||
|
Evofem Biosciences
EVFM
|
-22 K | - | 7.55 % | $ 38.1 M |